Table 2.
Age-sex weighted and test-adjusted seroprevalence estimates for anti-SARS-CoV-2 IgG antibodies.
| n | Seropos. | Seroprevalence (95% confidence interval) | |||
|---|---|---|---|---|---|
| Crude | Age-sex-weighted | Age-sex-weighted, test-adjusted | |||
| Overall | 971 | 302 | 31.1% (27.8–34.6) | 31.3% (27.9–34.9) | 29.2% (23.8–34.9) |
| Sex | |||||
| Female | 549 | 154 | 28.1% (23.7–32.8) | 28.0% (23.6–32.9) | 25.3% (19.0–32.2) |
| Male | 422 | 148 | 35.1% (30.3–40.1) | 34.6% (29.9–39.7) | 33.1% (26.4–40.5) |
| Age group | |||||
| 5–14 | 241 | 69 | 28.6% (22.2–36.0) | 28.7% (22.3–36.0) | 26.1% (17.6–35.6) |
| 15–29 | 325 | 98 | 30.2% (25.3–35.5) | 30.7% (25.8–36.0) | 28.5% (21.7–35.9) |
| 30–44 | 212 | 69 | 32.5% (26.4–39.4) | 32.7% (26.2–39.9) | 30.8% (22.3–40.4) |
| 45–64 | 153 | 51 | 33.3% (26.4–41.1) | 34.1% (27.1–41.8) | 32.5% (23.4–42.6) |
| 65+ | 40 | 15 | 37.5% (23.1–54.6) | 39.4% (24.4–56.6) | 38.7% (20.6–59.9) |
| Neighborhood | |||||
| Cité Verte | 72 | 16 | 22.2% (13.2–34.9) | 22.1% (13.1–34.8) | 18.4% (6.9–33.8) |
| Briqueterie | 106 | 37 | 34.9% (25.9–45.2) | 33.7% (25.2–43.3) | 32.0% (21.4–44.2) |
| Carriere | 236 | 72 | 30.5% (23.6–38.4) | 31.1% (24.0–39.3) | 29.0% (19.7–39.5) |
| Ekoudou | 190 | 65 | 34.2% (26.7–42.6) | 34.8% (27.4–43.0) | 33.3% (24.0–44.0) |
| Messa | 48 | 17 | 35.4% (18.0–57.9) | 35.7% (17.8–58.8) | 34.4% (12.9–62.4) |
| Mokolo | 96 | 27 | 28.1% (18.1–40.9) | 28.8% (17.7–43.4) | 26.3% (12.6–44.1) |
| Nkomkana | 75 | 18 | 24.0% (13.7–38.6) | 22.9% (12.6–37.9) | 19.3% (6.6–37.5) |
| Tsinga | 81 | 28 | 34.6% (26.8–43.3) | 35.3% (27.0–44.5) | 33.9% (23.5–45.7) |
| Tsinga Oliga | 67 | 22 | 32.8% (17.3–53.2) | 32.5% (16.7–53.6) | 30.6% (11.6–56.1) |
Confidence intervals for the crude- and age-sex-reweighted estimates are Wald-type intervals, while confidence intervals for the test-adjusted estimates were calculated by bootstrap sampling (see Methods).